ClinicalTrials.gg

Carcinoma, Hepatocellular clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 3,653 studies for Carcinoma, Hepatocellular across more than 10 countries. 1,065 are recruiting or about to start. 3,070 of them are mainly about Carcinoma, Hepatocellular (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-18. Counting its narrower condition Fibrolamellar hepatocellular carcinoma too: 3,666 studies, 1,068 open.

ClinicalTrials.gov finds 4,067 studies for Carcinoma, Hepatocellular. How that becomes 3,650 hereChecked on ClinicalTrials.gov . The studies here are updated every night.

This page counts the studies the registry files under Carcinoma, Hepatocellular, and those it files under no condition that list Carcinoma, Hepatocellularthemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. Only this comparison waits for its turn: it is asked again about once a week, so between two checks the registry's number can run a little ahead of it. How condition pages count

  1. 4,067Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −13Filed under a narrower condition, counted on its own pageFibrolamellar hepatocellular carcinoma 13
  3. −35List Carcinoma, Hepatocellular as a condition, but the registry did not file them under itMost often written as “Advanced Hepatocellular Carcinoma” (12), “Unresectable Hepatocellular Carcinoma” (5), and “Childhood Hepatocellular Carcinoma” (2). The registry filed them under other conditions only, most often Liver Neoplasms (17) and Carcinoma (5).
  4. −369Match it another way268 name it in the title, 3 in a keyword, and 98 by a synonym or other text the search reads.
  5. 3,650The count on this page266 of them list Carcinoma, Hepatocellular in their own words; the registry filed them under no condition.

Status

Completed
1,243
Recruiting
741
Status unknown
682
Terminated
297
Not yet recruiting
297
Active, not recruiting
210

Phase

Phase 2
1,225
Phase 1
677
Phase 3
341
Phase 4
110
Early Phase 1
59

Where

China
1,312
United States
926
Korea, Republic of
298
France
284
Taiwan
273
Italy
206

Who develops what

Add Carcinoma, Hepatocellular to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 71 programs from 52 companies, 50 with this as their studies’ main aim; 15 with a live phase 3 study; 20 primary completions in the next 12 months. Compare AstraZeneca, CSPC Pharmaceutical Group and Beijing Biotech here →

Stage, biomarker and line of therapy are not read yet: these programs are in development here, not all in the same competitive position.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
BevacizumabRecent, repeated
Evidence
  • NCT07813572 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · comparator · “Bevacizumab” · registered Sep 2026
  • NCT07490262 · Innovent Biologics, Inc. · Phase 3 · live · background · “Bevacizumab” · registered Mar 2026
  • NCT07479485 · Lepu Biopharma Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered Mar 2026
  • NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · background · “Bevacizumab” · registered Jan 2026
  • NCT06986785 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Bevacizumab” · registered May 2025
Hoffmann-La Roche48% of its industry studiesUS: Hoffmann-La Roche (FDA 2004) + 6 othersEU: Hoffmann-La Roche (EMA 2005) + 7 others1618 studies
lenvatinibRecent, repeated
Evidence
  • NCT07836530 · BeOne Medicines · Phase 3 · live · comparator · “Lenvatinib” · registered Sep 2026
  • NCT07540832 · Zhejiang Haichang Biotech Co., Ltd. · Phase 2 · live · background · “Lenvatinb” · registered Apr 2026
  • NCT07282509 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Lenvatinib Mesilate Capsules” · registered Nov 2025
  • NCT07219459 · CatalYm GmbH · Phase 2 · live · background · “Lenvatinib” · registered Oct 2025
  • NCT06986785 · Sichuan Biokin Pharmaceutical Co., Ltd. · Phase 2 · live · background · “Lenvatinib” · registered May 2025
Eisai Co., Ltd.63% of its industry studiesUS: Eisai Co., Ltd. (FDA 2015)EU: Eisai Co., Ltd. (EMA 2015)1113 studies
NivolumabRecent, repeated
Evidence
  • NCT07219459 · CatalYm GmbH · Phase 2 · live · background · “Nivolumab” · registered Oct 2025
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Nivolumab” · registered Mar 2024
  • NCT05919264 · Parabilis Medicines, Inc. · Phase 2 · live · background · “Nivolumab” · registered May 2023
  • NCT05257590 · TaiRx, Inc. · Phase 2 · live · background · “Nivolumab Injection [Opdivo]” · registered Feb 2022
  • NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Nivolumab” · registered Jan 2022
Bristol-Myers Squibb76% of its industry studiesUS: Bristol-Myers Squibb (FDA 2014)EU: Bristol-Myers Squibb (EMA 2015)77 studies
pembrolizumabRecent, repeated
Evidence
  • NCT07749586 · Arvinas Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jul 2026
  • NCT07282509 · CSPC Pharmaceutical Group Limited · Phase 2 · live · background · “Pembrolizumab Injection” · registered Nov 2025
  • NCT06400160 · Twinpig Biolab, Inc. · Phase 2 · live · background · “Keytruda” · registered Apr 2024
  • NCT05620134 · Shenzhen Salubris Pharmaceuticals Co., Ltd. · Phase 2 · live · background · “Pembrolizumab” · registered Nov 2022
  • NCT05440708 · Tvardi Therapeutics, Inc. · Phase 2 · live · background · “Pembrolizumab” · registered Jun 2022
Merck & Co., Inc74% of its industry studiesUS: Merck & Co., Inc (FDA 2014)EU: Merck & Co., Inc (EMA 2015)66 studies
atezolizumabRecent, repeated
Evidence
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Atezolizumab” · registered May 2026
  • NCT06921785 · AstraZeneca · Phase 3 · live · comparator · “Atezolizumab” · registered Mar 2025
  • NCT06109272 · AbbVie · Phase 3 · live · comparator · “Atezolizumab” · registered Oct 2023
  • NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Feb 2023
  • NCT05440708 · Tvardi Therapeutics, Inc. · Phase 2 · live · background · “Atezolizumab” · registered Jun 2022
Hoffmann-La Roche91% of its industry studiesUS: Hoffmann-La Roche (FDA 2016)EU: Hoffmann-La Roche (EMA 2017)66 studies
sintilimabRecent, repeated
Evidence
  • NCT07813572 · Suzhou Zelgen Biopharmaceuticals Co.,Ltd · Phase 3 · live · comparator · “Sintilimab” · registered Sep 2026
  • NCT06618664 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · live · comparator · “Sintilimab” · registered Sep 2024
  • NCT06530251 · Akeso · Phase 2 · live · comparator · “Sintilimab Injection” · registered Jul 2024
  • NCT05976568 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · comparator · “Sintilimab” · registered Jul 2023
Innovent Biologics, Inc.73% of its industry studies44 studies
IpilimumabRecent, repeated
Evidence
  • NCT07227012 · Pfizer · Phase 2 · live · background · “Ipilimumab” · registered Nov 2025
  • NCT06841185 · Fosun Pharma · Phase 3 · live · comparator · “US-sourced YERVOY®” · registered Feb 2025
  • NCT06362369 · 7 Hills Pharma, LLC · Phase 2 · live · background · “Ipilimumab” · registered Mar 2024
  • NCT05220722 · TriSalus Life Sciences, Inc. · Phase 2 · background · “Ipilimumab” · registered Jan 2022
  • NCT03241173 · Incyte Corporation · Phase 2 · background · “Ipilimumab” · registered Aug 2017
Bristol-Myers Squibb91% of its industry studiesUS: Bristol-Myers Squibb (FDA 2011)EU: Bristol-Myers Squibb (EMA 2011)44 studies
SorafenibRecent, repeated
Evidence
  • NCT07836530 · BeOne Medicines · Phase 3 · live · comparator · “Sorafenib” · registered Sep 2026
  • NCT06309485 · Zhejiang Haichang Biotech Co., Ltd. · Phase 2 · live · background · “Sorafenib 400 mg PO, BID” · registered Mar 2024
  • NCT05822752 · AbbVie · Phase 2 · live · comparator · “Sorafenib” · registered Apr 2023
  • NCT05033522 · Mirror Biologics, Inc. · Phase 3 · comparator · “Sorafenib” · registered Aug 2021
  • NCT04985136 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “Sorafenib” · registered Jul 2021
Bayer69% of its industry studiesUS: off-patent, 5 generics marketedEU: off-patent, 1 generic authorized33 studies
CapecitabineRecent, repeated
Evidence
  • NCT07490262 · Innovent Biologics, Inc. · Phase 3 · live · background · “Capecitabine” · registered Mar 2026
  • NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jan 2026
  • NCT05976568 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Capecitabine” · registered Jul 2023
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Capecitabine” · registered Aug 2021
  • NCT03563170 · ImmunityBio, Inc. · Phase 2 · background · “Capecitabine” · registered May 2018
Hoffmann-La Roche33% of its industry studiesEU: off-patent, 4 generics authorized33 studies
OxaliplatinRecent, repeatedPhase 4 trial recorded
Evidence
  • NCT07490262 · Innovent Biologics, Inc. · Phase 3 · live · background · “Oxaliplatin” · registered Mar 2026
  • NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · background · “Oxaliplatin injection” · registered Jan 2026
  • NCT05976568 · Qilu Pharmaceutical Co., Ltd. · Phase 3 · live · background · “Oxaliplatin injection” · registered Jul 2023
  • NCT05007106 · Merck & Co., Inc · Phase 2 · background · “Oxaliplatin” · registered Aug 2021
Sanofi35% of its industry studies33 studies
durvalumabRecent, repeated
Evidence
  • NCT06109272 · AbbVie · Phase 3 · live · comparator · “Durvalumab” · registered Oct 2023
  • NCT06111326 · Biocity Biopharmaceutics Co., Ltd. · Phase 2 · live · background · “Durvalumab injection” · registered Oct 2023
  • NCT05733598 · Replimune, Inc. · Phase 2 · live · background · “Durvalumab” · registered Feb 2023
AstraZeneca84% of its industry studiesUS: AstraZeneca (FDA 2017)EU: AstraZeneca (EMA 2018)33 studies
regorafenibRecent, repeated
Evidence
  • NCT07392866 · Nanjing Sanhome Pharmaceutical, Co., Ltd. · Phase 3 · live · comparator · “Regorafenib” · registered Jan 2026
  • NCT07310173 · Zhejiang Hisun Pharmaceutical Co. Ltd. · Phase 2 · live · comparator · “Regorafenib Tablets” · registered Dec 2025
  • NCT04985136 · Jiangsu HengRui Medicine Co., Ltd. · Phase 3 · comparator · “Regorafenib” · registered Jul 2021
Bayer80% of its industry studiesUS: Bayer (FDA 2012)EU: Bayer (EMA 2013)22 studies
Abiraterone AcetateRecent, repeated
Evidence
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Abiraterone” · registered May 2026
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Abiraterone” · registered Jun 2023
Johnson & Johnson65% of its industry studiesUS: off-patent, 11 generics marketedEU: off-patent, 2 generics authorized22 studies
enzalutamideRecent, repeated
Evidence
  • NCT07620574 · Exelixis · Phase 3 · live · background · “Enzalutamide” · registered May 2026
  • NCT05914116 · DualityBio Inc. · Phase 2 · live · background · “Enzalutamide” · registered Jun 2023
Astellas Pharma Inc45% of its industry studiesUS: Astellas Pharma Inc (FDA 2012)EU: off-patent, 1 generic authorized22 studies

27 more in limited or earlier use — sign in to see them, free.

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

In phase 3Company
HLX13☆ Track1 live phase-3 study: NCT06841185Fosun Pharma
Yttrium Y 90 Carbon Microspheres NRT6003☆ Track1 live phase-3 study: NCT06900543Chengdu New Radiomedicine Technology Co. LTD.
Anti-CTLA-4 Monoclonal Antibody IBI310☆ Track1 live phase-3 study: NCT07490262Innovent Biologics, Inc.
Anti-GPC3/Anti-4-1BB Bispecific Antibody BGB-B2033☆ Track1 live phase-3 study: NCT07836530BeOne Medicines
SH006☆ Track1 live phase-3 study: NCT07392866Nanjing Sanhome Pharmaceutical, Co., Ltd.

The 5 in phase 3 with the nearest primary completion, of 71 programs — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (20)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

  • 30 Nov 2026 est.tremelimumab, durvalumab · AstraZeneca · Phase 2 main aimNCT07081633 Durvalumab and Tremelimumab With Lenvatinib as First-line Treatment in Patients With Unresectable Hepatocellular Carcinoma — primary endpoint: Progression free survival (PFS) per RECIST 1.1 · 114 enrolled
  • 30 Nov 2026 est.cadonilimab · Akeso · Phase 2 main aimadded to lenvatinibNCT06984718 A Phase II Study of AK104 Combination With Lenvatinib Versus Lenvatinib for Second-line HCC — primary endpoint: Objective Response Rate (ORR) per RECIST v1.1 by Blinded Independent Central Review (BICR) · 120 enrolled
  • Dec 2026 est.Akt-1 Antisense Oligonucleotide WGI-0301 · Zhejiang Haichang Biotech Co., Ltd. · Phase 2 main aim+ Sorafenib 400 mg PO, BID continuously vs SorafenibNCT06309485 Phase 2 Study of WGI-0301 for Advanced HCC — primary endpoint: Efficacy of WGI-0301 in combination with Sorafenib based on ORR per RECIST 1.1. · 60 enrolled

17 more — sign in to see them all, free.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Carcinoma, Hepatocellular studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Immune checkpoint inhibitors 171 open · Tyrosine kinase inhibitors (TKIs) 97 open · Angiogenesis inhibitors 23 open · Antimetabolites 10 open · Alkylating agents 4 open

Coming up

334studies finish main data collection within a year22 of them phase 3

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest, phase 3 first

Who these studies take

Of the 741 Carcinoma, Hepatocellular studies recruiting now, 383 (52%) set no upper age limit and 251 (34%) stop at 75 or younger. 31 (4%) take children under 18. 0 (0%) are for women only and 0 (0%) for men only; 31 (4%) take healthy volunteers.

Recruiting studies that take each age, of 741
AgeWomenMen
1028 (4%)28 (4%)
18686 (93%)686 (93%)
30730 (99%)730 (99%)
40730 (99%)730 (99%)
50731 (99%)731 (99%)
65727 (98%)727 (98%)
75685 (92%)685 (92%)
85429 (58%)429 (58%)

Across all 3,653 studies, recruiting or not: 29% stop at 75 or younger and 3% at 65; 6% take children; <1% are for women only and <1% for men only; 4% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Carcinoma, Hepatocellular studies take

Of 430 phase 2 interventional studies under Carcinoma, Hepatocellular, half reached primary completion within 43 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 149 mo32–77 · 250 studies47 mo29–65 · 103 studies51 mo33–80 · 147 studies
Phase 1/253 mo38–76 · 136 studies47 mo35–74 · 72 studies—
Phase 243 mo30–71 · 430 studies38 mo23–50 · 80 studies47 mo33–78 · 350 studies
Phase 356 mo43–83 · 139 studies53 mo41–63 · 53 studies70 mo49–109 · 86 studies
Phase 468 mo24–118 · 38 studies——
Interventional, no phase47 mo23–75 · 385 studies—48 mo24–76 · 361 studies
Observational51 mo32–108 · 352 studies41 mo24–58 · 49 studies54 mo35–114 · 303 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 19, 2026.

Newly registered17

Show 12 more

Studies

Recruiting first, then most recently updated. Showing 50 of 3,653. Browse all 3,653 → or search them.